Lawmakers join groups urging MU delay

A bipartisan group of congressional leaders has joined other calls for a delay in the Meaningful Use program.

Reps. Renee Elmers (R-NC), Tom Price (R-Ga.) and David Scott (D-Ga.) are leading more than 100 other legislators in the effort.

The letter from Congress to Office of the Management and Budget (OMB) Director Shaun Donovan and Health and Human Services (HHS) Secretary Sylvia Burwell asks for the delay to “refocus the program to better serve patients and the providers who care for them.”

The deadlines imposed by the EHR incentive program are arbitrary, the legislators say, and assert that a delay in the final rules for Stage 3 and the 2015 Edition Certification “is necessary for the proper evaluation and optimization of implemented technology to ensure the technology can ensure better quality care for all patients.”

The College of Healthcare Information Management Executives (CHIME) offered its support for a delay. Although the organization supports the Meaningful Use program, "many hospitals and physician practices are still struggling to meet requirements under Stage 2," CHIME said in a statement. "According to data from the Centers for Medicare & Medicaid Services, only 1,826 hospitals successfully attested to Stage 2 in 2014. That's just 38 percent of hospitals that registered for the program. By comparison, 4,379 hospitals successfully attested for Stage 1 at least during the past five years."

CHIME staff held a high-level briefing with administration officials last Friday detailing how a delay would give all stakeholders time to address challenges to continued success of the Meaningful Use program, according to a notice. A pause in final rulemaking for Stage 3 would give policymakers, providers and vendors time to address the barriers to interoperability.

The Centers for Medicare & Medicaid Services (CMS) should also evaluate how new Medicare payment models will impact Stage 3 regulations, according to CHIME. In particular, the Merit-Based Payment System (MIPS) and Alternative Payment Models (APMs) were finalized after Stage 3 regulations were developed.

CHIME intends to "work with congressional leaders and the administration to ensure that the Meaningful Use program moves forward in a responsible way."

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.